Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;1(4):e96.
doi: 10.1002/cpz1.96.

In Vivo and Ex Vivo Patient-Derived Tumor Xenograft Models of Lymphoma for Drug Discovery

Maria Teresa Cacciapuoti  1 , Luca Vincenzo Cappelli  1   2 , Danilo Fiore  1 , Pedro Toruno  1 , Clarisse Kayembe  1 , Wayne Tam  1 , Giorgio Inghirami  1
Affiliations

In Vivo and Ex Vivo Patient-Derived Tumor Xenograft Models of Lymphoma for Drug Discovery

Maria Teresa Cacciapuoti et al. Curr Protoc. 2021 Apr.

Abstract

In the hemato-oncology field, remarkable scientific progress has been achieved, primarily propelled by the discovery of new technologies, improvement in genomics, and novel in vitro and in vivo models. The establishment of multiple cell line collections and the development of instrumental mouse models enhanced our ability to discover effective therapeutics. However, cancer models that faithfully mimic individual cancers are still imperfect. Patient-derived tumor xenografts (PDTXs) have emerged as a powerful tool for identifying the mechanisms which drive tumorigenesis and for testing potential therapeutic interventions. The recognition that PDTXs can maintain many of the donor samples' properties enabled the development of new strategies for discovering and implementing therapies. Described in this article are protocols for the generation and characterization of lymphoma PDTXs that may be used as the basis of shared procedures. Universal protocols will foster the model utilization, enable the integration of public and private repositories, and aid in the development of shared platforms. © 2021 Wiley Periodicals LLC. Basic Protocol 1: Tissue handling and cryopreservation of primary and PDTX samples Basic Protocol 2: Performing tumor implant in immunocompromised mice PDTX models Alternate Protocol 1: Intra-medullary femoral injection Alternate Protocol 2: Intravenous injection Alternate Protocol 3: Intraperitoneal injection Support Protocol 1: Phenotypical characterization of PDTXs by flow cytometry Support Protocol 2: Biological and molecular characterization of PDTX tumors by PCR detection of IGK, IGH, and TCR rearrangements Basic Protocol 3: Harvesting PDTX-derived tumor cells for ex vivo experiments Basic Protocol 4: In vivo testing of multiple compounds in a PDTX mouse model.

Keywords: PDTX; applications; clonal determination; drug discovery; genomic correspondence; immuno-phenotype; implants and routes; lymphoma; target therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • High-fat diet promotes tumor growth in the patient-derived orthotopic xenograft (PDOX) mouse model of ER positive endometrial cancer.
    Shen K, Shen D, Jin D, Zheng Y, Zhu Y, Zhao X, Zhang Z, Wang N, Chen H, Yang L. Shen K, et al. Sci Rep. 2023 Oct 2;13(1):16537. doi: 10.1038/s41598-023-43797-1. Sci Rep. 2023. PMID: 37783734 Free PMC article.
  • A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.
    Fiore D, Cappelli LV, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A, Han X, Taylor A, Chiu W, Fragliasso V, Tabbo F, Zamponi N, Di Siervi N, Kayembe C, Medico G, Patel RP, Gaudiano M, Machiorlatti R, Astone G, Cacciapuoti MT, Zanetti G, Pignataro C, Eric RA, Patel S, Zammarchi F, Zanettini C, Queiroz L, Nikitina A, Kudryashova O, Karelin A, Nikitin D, Tychinin D, Postovalova E, Bagaev A, Svekolkin V, Belova E, Tikhonova K, Degryse S, Xu C, Novero D, Ponzoni M, Tiacci E, Falini B, Song J, Khodos I, De Stanchina E, Macari G, Cafforio L, Gardini S, Piva R, Medico E, Ng SY, Moskowitz A, Epstein Z, Intlekofer A, Ahmed D, Chan WC, Martin P, Ruan J, Bertoni F, Foà R, Brody JD, Weinstock DM, Osan J, Santambrogio L, Elemento O, Betel D, Tam W, Ruella M, Cerchietti L, Rabadan R, Horwitz S, Inghirami G. Fiore D, et al. Cell Rep Med. 2025 Apr 15;6(4):102029. doi: 10.1016/j.xcrm.2025.102029. Epub 2025 Mar 26. Cell Rep Med. 2025. PMID: 40147445 Free PMC article.
  • Advances in the study of gastric organoids as disease models.
    Liu YY, Wu DK, Chen JB, Tang YM, Jiang F. Liu YY, et al. World J Gastrointest Oncol. 2024 May 15;16(5):1725-1736. doi: 10.4251/wjgo.v16.i5.1725. World J Gastrointest Oncol. 2024. PMID: 38764838 Free PMC article. Review.
  • EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.
    Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, Meydan C, Xia M, Shen H, Gutierrez J, Easwar Kumar V, Carrasco SE, Ouseph MM, Yamshon S, Martin P, Griess O, Shema E, Porazzi P, Ruella M, Brentjens RJ, Inghirami G, Zappasodi R, Chadburn A, Melnick AM, Béguelin W. Isshiki Y, et al. Cancer Cell. 2025 Jan 13;43(1):49-68.e9. doi: 10.1016/j.ccell.2024.11.006. Epub 2024 Dec 5. Cancer Cell. 2025. PMID: 39642889

References

Literature Cited

    1. Abate, F., Todaro, M., van der Krogt, J., Boi, M., Landra, I., Machiorlatti, R., … Inghirami, G. (2015). A novel patient derived tumorgraft model with TRAF1-ALK anaplastic large cell lymphoma translocation. Leukemia, 29, 1390-1401. doi: 10.1038/leu.2014.347.
    1. Bachmann, P. S., & Lock, R. B. (2007). In vivo models of childhood leukemia for preclinical drug testing. Current Drug Targets, 8, 773-783. doi: 10.2174/138945007780830809.
    1. Ben-David, U., Ha, G., Tseng, Y. Y., Greenwald, N. F., Oh, C., Shih, J., … Golub, T. R. (2017). Patient-derived xenografts undergo mouse-specific tumor evolution. Nature Genetics, 49, 1567-1575. doi: 10.1038/ng.3967.
    1. Bispo, J. A. B., Pinheiro, P. S., & Kobetz, E. K. (2020). Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harbor perspectives in medicine, 10, a034819. doi: 10.1101/cshperspect.a034819.
    1. Bondarenko, G., Ugolkov, A., Rohan, S., Kulesza, P., Dubrovskyi, O., Gursel, D., … Mazar, A. P. (2015). Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. Neoplasia, 17, 735-741. doi: 10.1016/j.neo.2015.09.004.

LinkOut - more resources